Literature DB >> 26985156

Our intraoperative boost radiotherapy experience and applications.

Semra Günay1, Ömür Alan2, Orhan Yalçın1, Aygen Türkmen3, Nihal Dizdar2.   

Abstract

OBJECTIVE: To present our experience since November 2013, and case selection criteria for intraoperative boost radiotherapy (IObRT) that significantly reduces the local recurrence rate after breast conserving surgery in patients with breast cancer.
MATERIAL AND METHODS: Patients who were suitable for IObRT were identified within the group of patients who were selected for breast conserving surgery at our breast council. A MOBETRON (mobile linear accelerator for IObRT) was used for IObRt during surgery.
RESULTS: Patients younger than 60 years old with <3 cm invasive ductal cancer in one focus (or two foci within 2 cm), with a histologic grade of 2-3, and a high possibility of local recurrence were admitted for IObRT application. Informed consent was obtained from all participants. Lumpectomy and sentinel lymph node biopsy was performed and advancement flaps were prepared according to the size and inclination of the conus following evaluation of tumor size and surgical margins by pathology. Distance to the thoracic wall was measured, and a radiation oncologist and radiation physicist calculated the required dose. Anesthesia was regulated with slower ventilation frequency, without causing hypoxia. The skin and incision edges were protected, the field was radiated (with 6 MeV electron beam of 10 Gy) and the incision was closed. In our cases, there were no major postoperative surgical or early radiotherapy related complications.
CONCLUSION: The completion of another stage of local therapy with IObRT during surgery positively effects sequencing of other treatments like chemotherapy, hormonotherapy and radiotherapy, if required. IObRT increases disease free and overall survival, as well as quality of life in breast cancer patients.

Entities:  

Keywords:  Breast cancer; boost radiotherapy; intraoperative radiotherapy; local recurrence

Year:  2015        PMID: 26985156      PMCID: PMC4771423          DOI: 10.5152/UCD.2015.2952

Source DB:  PubMed          Journal:  Ulus Cerrahi Derg        ISSN: 1300-0705


  17 in total

1.  The novel technique of delivering targeted intraoperative radiotherapy (Targit) for early breast cancer.

Authors:  Jayant S Vaidya; Michael Baum; Jeffrey S Tobias; Steven Morgan; Derek D'Souza
Journal:  Eur J Surg Oncol       Date:  2002-06       Impact factor: 4.424

Review 2.  Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials.

Authors:  M Clarke; R Collins; S Darby; C Davies; P Elphinstone; V Evans; J Godwin; R Gray; C Hicks; S James; E MacKinnon; P McGale; T McHugh; R Peto; C Taylor; Y Wang
Journal:  Lancet       Date:  2005-12-17       Impact factor: 79.321

3.  Long-term toxicity of an intraoperative radiotherapy boost using low energy X-rays during breast-conserving surgery.

Authors:  Uta Kraus-Tiefenbacher; Lelia Bauer; Antonella Scheda; Katharina Fleckenstein; Anke Keller; Carsten Herskind; Volker Steil; Frank Melchert; Frederik Wenz
Journal:  Int J Radiat Oncol Biol Phys       Date:  2006-08-02       Impact factor: 7.038

4.  Improving breast cancer surgery: a classification and quadrant per quadrant atlas for oncoplastic surgery.

Authors:  Krishna B Clough; Gabriel J Kaufman; Claude Nos; Ines Buccimazza; Isabelle M Sarfati
Journal:  Ann Surg Oncol       Date:  2010-02-06       Impact factor: 5.344

5.  IORT with electrons as boost strategy during breast conserving therapy in limited stage breast cancer: long term results of an ISIORT pooled analysis.

Authors:  Gerd Fastner; Felix Sedlmayer; Florian Merz; Heinrich Deutschmann; Roland Reitsamer; Christian Menzel; Christoph Stierle; Armando Farmini; Torsten Fischer; Antonella Ciabattoni; Alessandra Mirri; Eva Hager; Gabriele Reinartz; Claire Lemanski; Roberto Orecchia; Vincenzo Valentini
Journal:  Radiother Oncol       Date:  2013-07-02       Impact factor: 6.280

6.  Patient selection for accelerated partial-breast irradiation (APBI) after breast-conserving surgery: recommendations of the Groupe Européen de Curiethérapie-European Society for Therapeutic Radiology and Oncology (GEC-ESTRO) breast cancer working group based on clinical evidence (2009).

Authors:  Csaba Polgár; Erik Van Limbergen; Richard Pötter; György Kovács; Alfredo Polo; Jaroslaw Lyczek; Guido Hildebrandt; Peter Niehoff; Jose Luis Guinot; Ferran Guedea; Bengt Johansson; Oliver J Ott; Tibor Major; Vratislav Strnad
Journal:  Radiother Oncol       Date:  2010-02-22       Impact factor: 6.280

7.  Long-term results of targeted intraoperative radiotherapy (Targit) boost during breast-conserving surgery.

Authors:  Jayant S Vaidya; Michael Baum; Jeffrey S Tobias; Frederik Wenz; Samuele Massarut; Mohammed Keshtgar; Basil Hilaris; Christobel Saunders; Norman R Williams; Chris Brew-Graves; Tammy Corica; Mario Roncadin; Uta Kraus-Tiefenbacher; Marc Sütterlin; Max Bulsara; David Joseph
Journal:  Int J Radiat Oncol Biol Phys       Date:  2010-10-15       Impact factor: 7.038

8.  Breast-conserving surgery with or without radiotherapy: pooled-analysis for risks of ipsilateral breast tumor recurrence and mortality.

Authors:  Vincent Vinh-Hung; Claire Verschraegen
Journal:  J Natl Cancer Inst       Date:  2004-01-21       Impact factor: 13.506

9.  DEGRO practical guidelines for radiotherapy of breast cancer I: breast-conserving therapy.

Authors:  Marie-Luise Sautter-Bihl; Wilfried Budach; Jürgen Dunst; Petra Feyer; Wulf Haase; Wolfgang Harms; Felix Sedlmayer; Rainer Souchon; Frederik Wenz; Rolf Sauer
Journal:  Strahlenther Onkol       Date:  2007-12       Impact factor: 3.621

10.  Intraoperative radiation therapy: a critical analysis of the ELIOT and TARGIT trials. Part 2--TARGIT.

Authors:  Melvin J Silverstein; Gerd Fastner; Sergio Maluta; Roland Reitsamer; Donald A Goer; Frank Vicini; David Wazer
Journal:  Ann Surg Oncol       Date:  2014-08-20       Impact factor: 5.344

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.